​

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RCKT Stock Forecast

Rocket Pharmaceuticals (RCKT) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $3.83, with a high of $7.00 and a low of $2.00. This represents a -2.79% decline from the last price of $3.94.

- $6 $12 $18 $24 $30 High: $7 Avg: $3.83 Low: $2 Last Closed Price: $3.94

RCKT Stock Rating

Rocket Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 5 Hold (26.32%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 5 14 Strong Sell Sell Hold Buy Strong Buy

RCKT Price Target Upside V Benchmarks

TypeNameUpside
StockRocket Pharmaceuticals-2.79%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts115
Avg Price Target$7.00$7.00$16.50
Last Closing Price$3.94$3.94$3.94
Upside/Downside77.66%77.66%318.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-871-16
Sep, 25-971-17
Aug, 25278-118
Jul, 25287-118
Jun, 25277-117
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 03, 2025Leerink Partners$7.00$3.26114.72%77.66%
May 28, 2025Richard LawGoldman Sachs$2.00$2.48-19.35%-49.24%
May 28, 2025Andrew TsaiJefferies$2.50$2.480.81%-36.55%
Dec 30, 2024Yun ZhongWedbush$32.00$12.03166.00%712.18%
Nov 11, 2024Whitney IjemCanaccord Genuity$39.00$17.09128.20%889.85%
Sep 18, 2024Whitney IjemCanaccord Genuity$38.00$21.8074.31%864.47%
Sep 17, 2024Michael E UlzMorgan Stanley$45.00$21.18112.46%1042.13%
Apr 02, 2024Richard LawGoldman Sachs$39.00$26.7245.96%889.85%
Oct 03, 2022Raymond James$34.00$15.96113.03%762.94%
Aug 09, 2022Raymond James$24.00$15.1758.21%509.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 28, 2025Goldman SachsNeutralHolddowngrade
May 28, 2025Goldman SachsNeutralSelldowngrade
May 28, 2025Chardan CapitalBuyBuyhold
May 16, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 30, 2024WedbushOutperforminitialise
Dec 18, 2024JefferiesBuyinitialise
Sep 18, 2024Canaccord GenuityBuyBuyhold
Sep 17, 2024Morgan StanleyOverweightOverweighthold
Apr 02, 2024Goldman SachsNeutralinitialise
Sep 13, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-12 $1 $14 $27 $40 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.22$-2.92$-2.73----
Avg Forecast$-3.08$-3.07$-2.81$-2.28$-1.19$0.31$3.51
High Forecast$0.40$-2.71$-2.70$-0.70$0.59$36.49$7.88
Low Forecast$-11.58$-3.29$-2.87$-3.29$-2.21$-21.60$-0.03
Surprise %4.55%-4.89%-2.85%----

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$90.91K$990.00K$24.08K$58.34M$221.73M$512.27M$1.03B
High Forecast$284.34K$1.94M$47.07K$114.06M$433.48M$529.76M$2.02B
Low Forecast$11.90K$222.86K$5.42K$13.13M$49.91M$494.78M$232.19M
Surprise %-------

Net Income Forecast

$-2B $-900M $200M $1B $2B $4B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-219.38M$-245.59M$-258.75M----
Avg Forecast$-258.34M$-245.59M$-234.01M$-231.83M$-175.39M$-11.87M$295.17M
High Forecast$33.52M$-227.67M$-226.51M$-58.80M$49.84M$3.07B$661.61M
Low Forecast$-972.92M$-276.27M$-241.50M$-276.69M$-185.45M$-1.81B$-2.17M
Surprise %-15.08%-10.57%----

RCKT Forecast FAQ

Is Rocket Pharmaceuticals stock a buy?

Rocket Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rocket Pharmaceuticals is a favorable investment for most analysts.

What is Rocket Pharmaceuticals's price target?

Rocket Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $3.83 over the next 12 months. The price target range spans from $2 at the low end to $7 at the high end, suggesting a potential -2.79% change from the previous closing price of $3.94.

How does Rocket Pharmaceuticals stock forecast compare to its benchmarks?

Rocket Pharmaceuticals's stock forecast shows a -2.79% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rocket Pharmaceuticals over the past three months?

  • October 2025: 0% Strong Buy, 50.00% Buy, 43.75% Hold, 6.25% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 52.94% Buy, 41.18% Hold, 5.88% Sell, 0% Strong Sell.
  • August 2025: 11.11% Strong Buy, 38.89% Buy, 44.44% Hold, 0% Sell, 5.56% Strong Sell.

What is Rocket Pharmaceuticals’s EPS forecast?

Rocket Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.28, marking a -16.48% decrease from the reported $-2.73 in 2024. Estimates for the following years are $-1.19 in 2026, $0.31 in 2027, and $3.51 in 2028.

What is Rocket Pharmaceuticals’s revenue forecast?

Rocket Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $58.34M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $221.73M, followed by $512.27M for 2027, and $1.03B for 2028.

What is Rocket Pharmaceuticals’s net income forecast?

Rocket Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-232M, representing a -10.40% decrease from the reported $-259M in 2024. Projections indicate $-175M in 2026, $-11.874M in 2027, and $295.17M in 2028.